Your browser doesn't support javascript.
loading
Should prophylaxis against Pneumocystis jirovecii pneumonia be considered in selected patients with leprosy reactions?
Ramírez-Perea, Nuria; Moran-Castaño, Claudia; Perez-Molina, Jose A.
Afiliación
  • Ramírez-Perea N; Internal Medicine Department, Elda University Hospital, Alicante, 03600, Spain. Nuriaramirez92@outlook.es.
  • Moran-Castaño C; Internal Medicine Department, Carmen y Severo Ochoa Hospital, Asturias, Spain.
  • Perez-Molina JA; National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, 28034, Spain.
Pneumonia (Nathan) ; 16(1): 6, 2024 Apr 05.
Article en En | MEDLINE | ID: mdl-38576014
ABSTRACT
Leprosy reactions often require prolonged high-dose steroids or immunosuppressive drugs, putting patients at risk of Pneumocystis jirovecii pneumonia (PJP). However, no PJP cases are reported, possibly due to dapsone treatment for leprosy. In patients with leprosy reactions not receiving dapsone because of toxicity or resistance and requiring long-term immunosuppression, PJP prophylaxis should be considered.
Palabras clave

Texto completo: 1 Tema: Geral / Prevencao_controle Bases de datos: MEDLINE Idioma: En Revista: Pneumonia (Nathan) Año: 2024 Tipo del documento: Article

Texto completo: 1 Tema: Geral / Prevencao_controle Bases de datos: MEDLINE Idioma: En Revista: Pneumonia (Nathan) Año: 2024 Tipo del documento: Article